The results of this analysis from the RESCUE trial in patients with CKD stage 3–5 are consistent with the results of the phase 1/2 study, which showed that ziltivekimab was associated with significant improvement in markers of inflammation, reduced ESA requirements, and increased serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to ESA therapy.8 Here, ALB is linked to chronic kidney disease.